We don't know who is in there. We don't know what they are doing.
We are talking about a trillion dollars but we are also talking about over 130 million Americans.
This is an organization, the Department of Education, that spends some $683 million--spent $683 million this year on inf...
I'm very pleased to be able to support your nomination. I'm very impressed with what you've been able to do...
FDA's proposal to regulate LDTs is a significant change that would impose considerable new burdens on regulated parties.
Do you believe, as prior commissioners have--every one has told me this--that the Dietary Supplement Health and Educatio...
If we reduce that data exclusivity time, especially with regard to bio, you're talking about having to charge a lot more...
If we don't allow enough data exclusivity time, we're not going to develop these therapies, especially in bio, because b...
I hope that today's hearing will be another important step in our ongoing efforts to provide appropriate oversight and e...
I'm very concerned about data exclusivity.
The average cost, according to what I've been told, for a pharmaceutical drug is about a billion dollars...
Ranking Member Wyden and I will be making a formal referral to the HHS Office of Inspector General and the Department of...
inherently suspect
There is really an urgent need for more transparency.
the proliferation of PODs and the lack of guidance as to how these arrangements square with existing Federal law.
The patient has a right to know, and then, of course, taxpayers, because you have public payers, the people of this coun...
We believe these findings will say quite a bit about the lack of accountability for these types of business relationship...
One issue that significantly affects many entities in my home State is the FDA's October 2014 proposed guidance on the r...
